Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026

Executive Summary

• Helix BioPharma reported a net loss of $694 k for Q1‑2026 and $1.70 M for the first half, with cash on hand dwindling to $31 k.
• A previously signed subscription agreement for up to $33.37 M with Quantum Global Ventures collapsed after the investor declared bankruptcy, leaving the company without the expected proceeds.
• The company has entered a term‑sheet negotiation with Alumni Capital Limited for a potential financing, though terms remain undisclosed.

Key Details

• Financial Performance (Q1 2026): Net and total comprehensive loss of $694 k; loss per common share of $0.01.
• Six‑Month Results (ended Jan 31 2026): Net and total comprehensive loss of $1,702 k; loss per common share of $0.05.
• Cash Position: $31 k as of Jan 31 2026 vs. $1.996 M at the same date in 2025; insufficient to fund operations for the next twelve months.
• Prior Financing Attempt: Subscription agreement with Quantum Global Ventures AG for 18,538,889 common shares at $1.80/share (gross proceeds $33.37 M). Agreement fully executed but financing did not close due to investor bankruptcy.
• Current Financing Effort: Term sheet signed with Alumni Capital Limited for a potential financing; commercial terms are confidential.
• Operational Update: Closure of LDOS006 clinical trial in metastatic pancreatic adenocarcinoma contributed to reduced loss; R&D expenses increased due to accounting, tax, legal and consulting fees.

Notable Quotes

“While our current financial position reflects a challenging capital markets environment for small‑cap biotech companies, our focus remains firmly on securing the financing necessary to advance Helix into its next phase,” – Thomas Mehrling, MD, PhD, CEO

All forward‑looking statements are subject to risks and uncertainties as described in the release.